to 1985. The goal of this course was to examine solid tumors as complex organs and to discuss how the host-tumor interactions contributed to tumor progression, metastasis, and treatment resistance, areas not very popular or taught anywhere at that time.
INTRODUCTION
The Cancer Journal • Volume 21, Number 4, July/August 2015 www.journalppo.com Section I of this issue is dedicated to tumor vasculature as a target for therapy and begins with a review by Harold Dvorak on tumor stroma and antiangiogenesis approaches. It continues with an overview of angiogenesis with emphasis on the emerging concepts on the role of endothelial cell metabolism in angiogenesis by Peter Carmeliet. Section II is dedicated to reviews on tumor microenvironment and its role in cancer progression and treatment resistance. The first one discusses the role of stroma in tumor development by Zena Werb, the second one by Ian Tannock addresses the causes and consequences of limited distribution of anticancer drugs in tumors, and the last one by Suresh Mohla offers NCI's perspective on the importance of studying tumor microenvironment. Section III is dedicated to the biology and treatment of cancer metastasis. Bruce Zetter reviews the contribution of angiogenesis to metastasis, Robert Kerbel discusses the importance of preclinical modeling for drug development in metastatic diseases, and Isaiah J. Fidler provides an overview of the biology and challenges for therapy in brain metastatic disease. Section IV includes review on novel therapeutic strategies for cancer. It begins with a perspective from George Sledge on targeted therapies in the genomic era, continues with a summary by Daniel Von Hoff of advances in personalized cancer therapy, and ends with reviews by Rakesh Jain on targeting the tumor microenvironment in pediatric brain cancer treatment and by Robert Langer on using nanomedicine to target tumor microenvironment. Section V is on the role of biomarkers in cancer therapies. Herbert Hurwitz discusses the identification of blood-based protein biomarkers for antiangiogenic therapy; Marsha Moses summarizes the efforts on mining the human proteome for urine-based biomarker discovery, and Gregory Sorensen sums up the use of vascular magnetic resonance imaging as imaging biomarker for antiangiogenic therapy of brain tumors. Last section is dedicated to reviews on the role of the immune microenvironment in cancer therapy. Lisa Coussens discusses the role of myeloid cells as targets for therapy in solid tumors, and Thomas Tedder focuses on the role of tumor microenvironment in immunotherapy for lymphoma.
We are grateful to the course faculty and participants who have contributed to this course over the past 30 years, to the continuing education staff of Carnegie Mellon University and Harvard Medical School, and to various pharmaceutical and biotechnology companies that have provided educational grants for the course. We would like to dedicate this issue to the late Drs Gullino, Folkman, and Maciag for their seminal contributions to these areas of investigation. We sincerely hope that the readers of this special volume will see the excitement and potential for successful clinical translation of research in tumor microenvironment.
